FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - December 5, 2025 277 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR One Year of Adjuvant T-DM1 Leads to Outstanding Long-Term Outcomes Among... July 18, 2024 Ibrutinib-Containing Immunochemotherapy in Front-Line Treatment of Young, Medically Fit Patients with... May 14, 2024 ESMO Calls for Concerted Action to Prevent Burnout and Foster Well-Being... September 10, 2024 Fragment Analysis Is a More Reliable MET Exon 14 Screening Strategy... October 9, 2020 Load more HOT NEWS Trastuzumab Deruxtecan Shows Antitumour Activity and Durable Responses in Heavily Pretreated... Laser-Based Device Detects and Kills Melanoma Cells in the Blood, Study... Man Gets His First Haircut In 15 Years To Join The... ESMO 2022: New Research in Treating Gastrointestinal and Genitourinary Cancers
